DXC011 / Hangzhou DAC Biotech - LARVOL DELTA

DXC011, a novel dual-payload antibody-drug conjugate targeting folate receptor alpha (AACR 2026) - "Although an FRα-directed ADC Elahere has already achieved clinical approval, this microtubule inhibitor-based agent faces challenges, such as ocular toxicity, narrow therapeutic windows, and limited activity beyond ovarian cancer. Collectively, these findings indicate that DXC011 offers an improved therapeutic index and may enable expanded indication coverage. DXC011 represents a novel FRα-targeted dual-payload ADC that achieves potent and broad antitumor activity with enhanced tolerability, supporting its advancement toward clinical development."

ADC • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1